GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
Frontiers in Cell and Developmental Biology2020Vol. 8, pp. 562522–562522
Citations Over TimeTop 21% of 2020 papers
Abstract
With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson's disease and dementia with Lewy bodies.
Related Papers
- → Aggregation and beyond: alpha-synuclein-based biomarkers in synucleinopathies(2023)31 cited
- → Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies(2022)19 cited
- → Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies(2003)140 cited
- → Aggregation of ?-synuclein in the pathogenesis of Parkinson?s disease(2003)76 cited
- → Characterization of exosomes as a diagnostic marker in neurodegenerative diseases(2016)